Lipid Nanosystems and Serum Protein as Biomimetic Interfaces: Predicting the Biodistribution of a Caffeic Acid-Based Antioxidant

Abstract

AntiOxCIN 3 is a novel mitochondriotropic antioxidant developed to minimize the effects of oxidative stress on neurodegenerative diseases. Prior to an investment in preclinical in vivo studies, it is important to apply in silico and biophysical cell-free in vitro studies to predict AntiOxCIN 3 biodistribution profile, respecting the need to preserve animal health in accordance with the EU principles (Directive 2010/63/EU). Accordingly, we propose an innovative toolbox of biophysical studies and mimetic models of biological interfaces, such as nanosystems with different compositions mimicking distinct membrane barriers and human serum albumin (HSA). Methods: Intestinal and cell membrane permeation of AntiOxCIN 3 was predicted using derivative spectrophotometry. AntiOxCIN 3-HSA binding was evaluated by intrinsic fluorescence quenching, synchronous fluorescence, and dynamic/electrophoretic light scattering. Steady-state and time-resolved fluorescence quenching was used to predict AntiOxCIN 3membrane orientation. Fluorescence anisotropy, synchrotron small-and wide-angle X-ray scattering were used to predict lipid membrane biophysical impairment caused by AntiOxCIN 3 distribution. Results and Discussion: We found that AntiOxCIN 3 has the potential to permeate the gastrointestinal tract. However, its biodistribution and elimination from the body might be affected by its affinity to HSA (>90%) and by its steady-state volume of distribution (VD SS =1.89 ± 0.48 L•Kg −1). AntiOxCIN 3 is expected to locate parallel to the membrane phospholipids, causing a bilayer stiffness effect. AntiOxCIN 3 is also predicted to permeate through blood-brain barrier and reach its therapeutic target-the brain. Conclusion: Drug interactions with biological interfaces may be evaluated using membrane model systems and serum proteins. This knowledge is important for the characterization of drug partitioning, positioning and orientation of drugs in membranes, their effect on membrane biophysical properties and the study of serum protein binding. The analysis of these interactions makes it possible to collect valuable knowledge on the transport, distribution, accumulation and, eventually, therapeutic impact of drugs which may aid the drug development process.

Nano‐biotechnology in tumour and cancerous disease: A perspective review

“…Some of these successful studies could be the reference point for the future towards targeted therapy and may add towards the need for more advancement in molecular medicine. This technology would allow nanometre‐sized constructs to be used to deliver the drug to the desired location with a longer half‐life to treat the disease 231–233 …”